{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["22(12)"],"submitter":["Franc S"],"pubmed_abstract":["<b><i>Background:</i></b> The DIABEO<sup>®</sup> system (DS) is a telemedicine solution that combines a mobile app for patients with a web portal for health care providers. DS allows real-time monitoring of basal-bolus insulin therapy as well as therapeutic decision-making, integrating both basal and bolus dose calculation. Real-life studies have shown a very low rate of use of mobile health applications by patients. Therefore, we conducted a large randomized controlled trial study to investigate the efficacy of DS in conditions close to real life (TELESAGE study). <b><i>Methods:</i></b> TELESAGE was a multicenter, randomized, open study with three parallel arms: arm 1 (standard care), arm 2 (DIABEO alone), and arm 3 (DIABEO+telemonitoring by trained nurses). The primary outcome assessed t"],"journal":["Diabetes technology & therapeutics"],"pagination":["904-911"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7757616"],"repository":["biostudies-literature"],"pubmed_title":["DIABEO System Combining a Mobile App Software With and Without Telemonitoring Versus Standard Care: A Randomized Controlled Trial in Diabetes Patients Poorly Controlled with a Basal-Bolus Insulin Regimen."],"pmcid":["PMC7757616"],"pubmed_authors":["Simon P","Catargi B","Jeandidier N","Borot S","Penfornis A","Farret A","Reznik Y","Fontaine P","d'Orsay G","Serusclat P","Detournay B","Chaillous L","Schaepelynck P","Guerci B","Hanaire H","Franc S","Benhamou PY","Kherbachi Y","Charpentier G"],"additional_accession":[]},"is_claimable":false,"name":"DIABEO System Combining a Mobile App Software With and Without Telemonitoring Versus Standard Care: A Randomized Controlled Trial in Diabetes Patients Poorly Controlled with a Basal-Bolus Insulin Regimen.","description":"<b><i>Background:</i></b> The DIABEO<sup>®</sup> system (DS) is a telemedicine solution that combines a mobile app for patients with a web portal for health care providers. DS allows real-time monitoring of basal-bolus insulin therapy as well as therapeutic decision-making, integrating both basal and bolus dose calculation. Real-life studies have shown a very low rate of use of mobile health applications by patients. Therefore, we conducted a large randomized controlled trial study to investigate the efficacy of DS in conditions close to real life (TELESAGE study). <b><i>Methods:</i></b> TELESAGE was a multicenter, randomized, open study with three parallel arms: arm 1 (standard care), arm 2 (DIABEO alone), and arm 3 (DIABEO+telemonitoring by trained nurses). The primary outcome assessed t","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Dec","modification":"2025-04-26T20:10:38.877Z","creation":"2021-02-20T17:34:55Z"},"accession":"S-EPMC7757616","cross_references":{"pubmed":["32407148"],"doi":["10.1089/dia.2020.0021"]}}